Country: Canada
Language: English
Source: Health Canada
POMALIDOMIDE
NATCO PHARMA (CANADA) INC
L04AX06
POMALIDOMIDE
2MG
CAPSULE
POMALIDOMIDE 2MG
ORAL
100
Prescription
Active ingredient group (AIG) number: 0155290002; AHFS:
APPROVED
2023-02-22
_POMALIDOMIDE Product Monograph _ _ _ _ _ _Page 1 of 49_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR POMALIDOMIDE Pomalidomide 1 mg, 2 mg, 3 mg and 4 mg Capsules for Oral Use Antineoplastic Agent Immunomodulatory Agent ATC Code: L04AX06 Natco Pharma (Canada) Inc. Date of Preparation: 2000 Argentia Road, Plaza 1, Suite 200 June 15, 2021 Mississauga, Ontario L5N 1P7 Submission Control No: 245625 _POMALIDOMIDE Product Monograph _ _ _ _ _ _Page 2 of 49_ RECENT MAJOR LABEL CHANGES Not applicable. TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED . RECENT MAJOR LABEL CHANGES............................................................................................ 2 TABLE OF CONTENTS .............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ..................................................................... 4 1 INDICATIONS .............................................................................................................. 4 1.1 Pediatrics .......................................................................................................... 4 1.2 Geriatrics........................................................................................................... 4 2 CONTRAINDICATIONS ................................................................................................. 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ............................................................ 5 4 DOSAGE AND ADMINISTRATION................................................................................. 5 4.1 Dosing Considerations ....................................................................................... 5 4.2 Recommended Dose and Dosage Adjustment..................................................... 6 4.4 Administration................................................................................................... 8 4.5 Missed Dose Read the complete document